<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Vis</journal-id><journal-id journal-id-type="publisher-id">MV</journal-id><journal-title>Molecular Vision</journal-title><issn pub-type="epub">1090-0535</issn><publisher><publisher-name>Molecular Vision</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">46</article-id><article-id pub-id-type="publisher-id">2009MOLVIS0008</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Relationship between the expression of cyclooxygenase-2 and survivin in primary pterygium</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Maxia</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Perra</surname><given-names>Maria Teresa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Demurtas</surname><given-names>Paolo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Minerba</surname><given-names>Luigi</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Murtas</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Piras</surname><given-names>Franca</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cabrera</surname><given-names>Ren&#x000e8;</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ribatti</surname><given-names>Domenico</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sirigu</surname><given-names>Paola</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><aff id="aff1"><label>1</label>Department of Cytomorphology, University of Cagliari Medical School, Cagliari, Italy</aff><aff id="aff2"><label>2</label>Department of Public Health, University of Cagliari Medical School, Cagliari, Italy</aff><aff id="aff3"><label>3</label>Department of Ophthalmology, University of Cuenca Medical School, Cuenca, Ecuador</aff><aff id="aff4"><label>4</label>Department of Human Anatomy and Histology, University of Bari Medical School, Bari, Italy</aff><aff id="aff5"><label>5</label>Instituto del Cancer &#x02018;Solca&#x02019;, Cuenca, Ecuador</aff></contrib-group><author-notes><fn><p>The first two authors contributed equally to this work.</p></fn><corresp id="cor1">Correspondence to: Dr. Cristina Maxia, Department of Cytomorphology, University of Cagliari, Cittadella Universitaria, 09042, Monserrato (CA) &#x02013; Italy; Phone: +39 070 6754005; FAX: +39 070 6754003; email: <email xlink:href="cmaxia@unica.it">cmaxia@unica.it</email></corresp></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>27</day><month>2</month><year>2009</year></pub-date><volume>15</volume><fpage>458</fpage><lpage>463</lpage><history><date date-type="received"><day>09</day><month>1</month><year>2009</year></date><date date-type="accepted"><day>23</day><month>2</month><year>2009</year></date></history><permissions><copyright-year>2009</copyright-year><copyright-holder>Molecular Vision</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title>Purpose</title><p>To investigate the expression of cyclooxygenase-2 (COX-2) in a group of 93 Ecuadorian primary pterygia and to evaluate a possible association between COX-2 and survivin.</p></sec><sec sec-type="methods"><title>Methods</title><p>Primary pterygium samples were treated for the immunohistochemical evaluation of COX-2 and survivin. Mouse monoclonal antibody to COX-2 and rabbit polyclonal antibody to survivin were used. Statistical analysis was performed using the SPSS statistical software package, version 15.0.</p></sec><sec><title>Results</title><p>In our study, 63 (67.7%) primary pterygia samples were positive for COX-2 staining, and 70 (75.3%) specimens were positive for survivin expression. In the group of pterygia with survivin immunostaining, there were 55 (78.6%) samples with COX-2 expression. The staining of both COX-2 and survivin was localized in the lower and middle layers of the epithelium. When analyzed by Fisher's exact test, the expression of COX-2 showed a strong significant correlation with survivin (p=0.0002).</p></sec><sec><title>Conclusions</title><p>These data, showing a significant correlation between COX-2 and survivin in primary pterygium, suggest that pterygium may originate through an anti-apoptotic mechanism.</p></sec></abstract><custom-meta-wrap><custom-meta><meta-name>GalleyStatus</meta-name><meta-value>Export to XML</meta-value></custom-meta><custom-meta><meta-name>corr-author</meta-name><meta-value>Maxia</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Pterygium is a common conjunctival disorder exhibiting degenerative and hyperplastic changes as well as proliferative, inflammatory features and a rich vasculature. Although extracellular matrix remodeling [<xref ref-type="bibr" rid="r1">1</xref>], inflammatory process [<xref ref-type="bibr" rid="r2">2</xref>,<xref ref-type="bibr" rid="r3">3</xref>], anti-apoptotic mechanisms [<xref ref-type="bibr" rid="r4">4</xref>,<xref ref-type="bibr" rid="r5">5</xref>], cytokines [<xref ref-type="bibr" rid="r6">6</xref>], growth and angiogenic factors [<xref ref-type="bibr" rid="r7">7</xref>,<xref ref-type="bibr" rid="r8">8</xref>], and viral infection [<xref ref-type="bibr" rid="r9">9</xref>,<xref ref-type="bibr" rid="r10">10</xref>] have been proposed as causative agents in its pathogenesis, several investigators consider pterygium an ultraviolet radiation (UV)-related disease [<xref ref-type="bibr" rid="r11">11</xref>-<xref ref-type="bibr" rid="r16">16</xref>]. Pterygium has long been considered as a chronic degenerative condition; however, because of the finding of abnormal expression of p53 protein in the epithelium [<xref ref-type="bibr" rid="r17">17</xref>-<xref ref-type="bibr" rid="r21">21</xref>], pterygium has been considered an UV-related tumor rather than a degenerative disease. To support this hypothesis, we reported in a previous study the presence of conjunctival melanocytic pigmented lesions in pterygium and, among these, two primary acquired melanosis with atypia [<xref ref-type="bibr" rid="r22">22</xref>].</p><p>UV irradiation has a key role in the formation of reactive oxygen species (ROS), short-lived entities continuously generated at low levels during the course of normal aerobic metabolism, which have been associated with inflammation, initiation, and progression of tumors through activation of carcinogens [<xref ref-type="bibr" rid="r23">23</xref>]. ROS can induce cyclooxygenase 2 (COX-2) production [<xref ref-type="bibr" rid="r24">24</xref>]. COXs are rate-limiting enzymes involved in prostanoid synthesis, which convert arachidonic acid into prostaglandin (PG) H2, a substrate for specific prostaglandin synthases [<xref ref-type="bibr" rid="r25">25</xref>]. Two isoforms of COX, encoded by separate genes, have been isolated, cloned, and sequenced. The isoform designated as COX-1, constitutively expressed in most cells and tissues, modulates normal physiologic responses such as regulation of renal and vascular homeostasis and gastroprotection. The other one, designed as COX-2, is rapidly induced by growth factors, cytokines, hormones, hypoxia, bacterial endotoxins, tumor promoters, and UV light, and its protein is frequently undetectable at baseline in most normal adult tissues. Both ROS and COX-2 play an important role in UV-related cutaneous carcinogenesis [<xref ref-type="bibr" rid="r26">26</xref>]. Subbaramaiah et al. [<xref ref-type="bibr" rid="r27">27</xref>] reported that COX-2 expression is suppressed by normal p53, suggesting that loss of p53 function may result in the induction of COX-2 expression. Consistent overexpression of COX-2 was observed in a broad range of premalignant, malignant, and metastatic human epithelial cancers [<xref ref-type="bibr" rid="r28">28</xref>].</p><p>Aziz and co-authors [<xref ref-type="bibr" rid="r29">29</xref>] demonstrated that UV-B exposure leads to a significant activation of survivin, a member of the inhibitor of apoptosis protein family (IAPs) that is overexpressed in most human malignancies and implicated in the cellular stress response. It is well known that the functional loss of wild-type p53 is associated with the upregulation of survivin expression in several types of tumors. Recently, we have demonstrated in pterygium a significant association between survivin expression and oxidative stress and p53, and we have hypothesized a UV-related loss of normal p53 functionality [<xref ref-type="bibr" rid="r5">5</xref>].</p><p>Since several studies demonstrated a correlation between COX-2 and survivin expression in tumors [<xref ref-type="bibr" rid="r30">30</xref>-<xref ref-type="bibr" rid="r32">32</xref>], the aim of the present study was to investigate the expression of COX-2 in a group of 93 Ecuadorian primary pterygia by immunohistochemistry and to evaluate a possible association between COX-2 and survivin.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients and study design</title><p>This study was based on an analysis of formalin-fixed, paraffin embedded primary pterygia harvested from 93 patients (36 males and 57 females) in a cluster of 111 people that underwent excision by bare sclera technique at the Department of Pathology at the Cancer Center of SOLCA (Cuenca, Ecuador) from July 2004 to December 2007. The selected patients were of mixed race, between American Indian and Hispanic. Ages ranged between 18 and 77 years (mean age 43.35&#x000b1;13.9). Thirty-five patients lived in the countryside and 58 in an urban setting. All the selected patients were outdoor workers. Most of the lesions were located on the nasal side and only the head of primary pterygium was used as the pterygium sample. Pterygium morphology was clinically graded as atrophic (24 cases), intermediate (53 cases), or fleshy (17 cases) according to an assessment of pterygium translucency. Normal conjunctiva samples as controls were collected from medial bulbar conjunctiva of 10 patients (six males and four females) without pterygium and pinguecula who underwent cataract surgery. Ages ranged between 25 and 70 years (mean age 52.1&#x000b1;16.02). The younger patients were surgically treated for traumatic cataract. Seven patients lived in the countryside and three resided in an urban setting. Relevant clinical features of the patients are summarized in <xref ref-type="table" rid="t1">Table 1</xref>. Patients did not receive any medication before surgery except for a topical anesthetic, and no drugs or chemical agents were used during surgical operation. The study protocol was approved by the local research ethic committee, and informed consent was obtained from all subjects according to the World Medical Association Declaration of Helsinki. Complete information on patients was available in all cases.</p><table-wrap id="t1" position="float"><label>Table 1</label><caption><title>Clinical features of the patients.</title></caption><table frame="hsides" rules="groups"><col width="68" span="1"/><col width="117" span="1"/><col width="54" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Samples</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Variables</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Number of patients</bold></th></tr></thead><tbody><tr><td colspan="3" valign="top" align="left" scope="col" rowspan="1"><bold>Pterygium</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td colspan="2" valign="top" align="left" rowspan="1"><bold>Gender</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Male<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">36<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Female<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">57<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td colspan="2" valign="top" align="left" rowspan="1"><bold>Age</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02264; 43*<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">47<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e; 43*<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">46<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td colspan="2" valign="top" align="left" rowspan="1"><bold>Residency</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Urban<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">58<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Rural<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">35<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td colspan="2" valign="top" align="left" rowspan="1"><bold>COX-2 expression</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Positive<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">63<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Negative<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">30<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td colspan="2" valign="top" align="left" rowspan="1"><bold>Survivin expression</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Positive<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">70<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Negative<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">23<hr/></td></tr><tr><td colspan="3" valign="top" align="left" scope="col" rowspan="1"><bold>Conjunctiva</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td colspan="2" valign="top" align="left" rowspan="1"><bold>Gender</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Male<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Female<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td colspan="2" valign="top" align="left" rowspan="1"><bold>Age</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c; 55*<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;55*<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td colspan="2" valign="top" align="left" rowspan="1"><bold>Residency</bold><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Urban<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Rural</td><td valign="top" align="center" rowspan="1" colspan="1">7</td></tr></tbody></table><table-wrap-foot><p>This table presents clinical variables of the study&#x02019;s participants and the immunohistochemical analysis. The asterisk indicates the median value.</p></table-wrap-foot></table-wrap></sec><sec><title>Immunohistochemistry</title><p>Microtome histological sections (6&#x02013;7&#x000a0;&#x003bc;m thick) were treated for the immunohistochemical demonstration of COX-2 and survivin using the streptavidin-biotin alkaline phosphatase method. They were dewaxed in xylene and rehydrated in a graded alcohol series and phosphate-buffered saline (PBS). Water-bath, heating-based antigen retrieval was performed by immersion in 10&#x000a0;mM citrate buffer solution (pH 6.0) at 95&#x000a0;&#x000b0;C for 40 min. After gradual cooling for 20 min, sections were treated for 45 min with 10% normal goat or normal horse serum in PBS. Mouse monoclonal antibody (1:100, clone 4H12; Novocastra, Newcastle upon Tyne, UK) to human COX-2 raised against amino acids 30&#x02013;163 of the NH<sub>2</sub>-terminus of human COX-2 molecule and rabbit polyclonal antibody (1:1000; Novus Biologicals, Littleton, CO) to recombinant human survivin protein, which recognizes the full-length recombinant human survivin, were used as primary antisera and incubated for 60 min at room temperature while biotinylated anti-mouse and anti-rabbit IgG were used as secondary antisera (1:200; Vector Laboratories, Burlingame, CA) and incubated for 30 min at room temperature. The sections were further incubated in alkaline phosphatase streptavidin (1:1000; Vector Laboratories) for 30 min at room temperature and reacted with Fast Red Substrate System (Dako, Glostrup, Denmark). All sections were thoroughly rinsed in PBS between each step, and finally counterstained with Mayer hematoxylin and mounted in glycerol gelatin (Sigma, St. Louis, MO).</p><p>Sections of Crohn&#x02019;s disease were used as positive control tissue for COX-2, while sections of human cutaneous malignant melanoma were used as positive control for survivin. Negative controls were obtained by omission of the primary antibody or by replacing the primary antibody with an isotype-matched antibody. Positive and negative controls were run simultaneously.</p><p>Micrographs were captured by a digital camera Canon PowerShot A620, (Canon Inc., Tokyo, Japan) on a microscope Zeiss Axiophot (Carl Zeiss Inc., Oberkochen, Germany), and processed by Adobe Photoshop (version 7.0; Adobe Systems, Inc., San Jose, CA) software.</p></sec><sec><title>Evaluation of immunoreactivity</title><p>Results were independently evaluated by three observers in a blinded fashion. Four to six 200X fields covering almost the whole of each of the four sections per sample were examined with a 144-intersection point square reticulum (0.78&#x000a0;mm<sup>2</sup>) inserted in the eyepiece and scored for the percentage of epithelial immunoreactive cells. The cutoff level for immunohistochemical analysis was set at 10%, meaning that those samples with more than 10% of cells stained were considered to be positive. Patients were divided into four groups, COX-2-positive, COX-2-negative, survivin-positive, and survivin-negative.</p></sec><sec><title>Statistics</title><p>The results were assessed with Fisher&#x02019;s exact test. Data were computed by the SPSS statistical software package, version 15.0 (SPSS Inc., Chicago, IL). A p value of less than 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>COX-2 expression</title><p>In our study, 63 (63/93, 67.7%) primary pterygia samples were positive for COX-2 staining. The staining was detectable in the cytoplasm of cells localized to the basal and middle layers of the epithelium and in the endothelial cells of microvessels (<xref ref-type="fig" rid="f1">Figure 1A</xref>). No immunostaining for COX-2 in normal conjunctiva was present (<xref ref-type="fig" rid="f2">Figure 2E</xref>). Positive control section from Crohn&#x02019;s disease demonstrated immunoreactivity for COX-2 in the cytoplasm of both epithelial cells located in the crypts, surface epithelial cells, and mononuclear cells of the lamina propria (<xref ref-type="fig" rid="f2">Figure 2A</xref>). No staining was detected when the primary antibody was omitted (<xref ref-type="fig" rid="f2">Figure 2B</xref>) or when an isotype control antibody was applied.</p><fig id="f1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>Immunohistochemical staining for COX-2 and survivin in adjacent sections of primary pterygium. The expression of both COX-2 (<bold>A</bold>) and survivin (<bold>B</bold>) was localized in the lower and middle layers of the epithelium. The immunoreactivity for survivin was localized to the nuclei and cytoplasm, while COX-2 expression was limited to cytoplasm. Note in <bold>A</bold>, COX-2-immunoreactive endothelial cells in the lamina propria. Each section was counterstained with hematoxylin. Original magnification; 400X.</p></caption><graphic xlink:href="mv-v15-458-f1"/></fig><fig id="f2" fig-type="figure" position="float"><label>Figure 2</label><caption><p>Immunohistochemical staining for COX-2, and survivin in control sections. Sections from Crohn&#x02019;s disease (<bold>A</bold>) and human cutaneous malignant melanoma (<bold>C</bold>) were included as positive controls. No immunostaining for COX-2 (<bold>E</bold>) and survivin (<bold>F</bold>) in normal conjunctiva was observed. Sections incubated without a primary antibody (inset <bold>B</bold>) or with an isotype control antibody (inset <bold>D</bold>) displayed no immunoreactivity. Each section was counterstained with hematoxylin. Original magnification, <bold>A</bold>: 200X; <bold>C</bold>,<bold>E</bold>,<bold>F</bold>: 400X; insets <bold>B</bold>,<bold>D</bold>: 400X.</p></caption><graphic xlink:href="mv-v15-458-f2"/></fig></sec><sec><title>Survivin expression</title><p>Positive staining was detected in 70 (70/93, 75.3%) primary pterygia. The immunoreactivity was localized to the nuclei and cytoplasm of the epithelial cells (<xref ref-type="fig" rid="f1">Figure 1B</xref>). No substantial staining was visible in the subepithelial fibrovascular layers. No immunostaining for survivin in normal conjunctiva was detectable (<xref ref-type="fig" rid="f2">Figure 2F</xref>). The positive control section from human cutaneous melanoma demonstrated immunoreactivity for survivin in the nuclei and cytoplasm of tumoral cells (<xref ref-type="fig" rid="f2">Figure 2C</xref>). Reactivity was absent in sections incubated without primary antibody, and no reactivity developed when the isotype control antibody was used (<xref ref-type="fig" rid="f2">Figure 2D</xref>).</p></sec><sec><title>Relationship between COX-2 and survivin</title><p>The relationship between COX-2 and survivin is shown in <xref ref-type="table" rid="t2">Table 2</xref>. In the group of pterygia positive to survivin, 55/70 (78.6%) samples showed COX-2 expression. When analyzed by Fisher's exact test, the expression of total survivin showed a strong significant correlation with COX-2 (p=0.0002).</p><table-wrap id="t2" position="float"><label>Table 2</label><caption><title>Relationship between COX-2 and survivin<bold>.</bold></title></caption><table frame="hsides" rules="groups"><col width="116" span="1"/><col width="60" span="1"/><col width="63" span="1"/><col width="38" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Group of patients</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Survivin positive</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Survivin negative</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Total</bold></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>COX-2 positive</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">55<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">63<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>COX-2 negative</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">15<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">15<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">30<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Total</bold></td><td valign="top" align="center" rowspan="1" colspan="1">70</td><td valign="top" align="center" rowspan="1" colspan="1">23</td><td valign="top" align="center" rowspan="1" colspan="1">93</td></tr></tbody></table><table-wrap-foot><p>Shown is the relationship between COX-2 and survivin. In the group of pterygia with survivin immunostaining, there were 55 (55/70, 78.6%) samples with COX-2 expression. Survivin expression was significantly associated with COX-2 positivity (p=0.0002 assessed by Fisher&#x02019;s exact test).</p></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>UV light is one of the most important factors involved in the pathogenesis of pterygium, but the mechanism by which UV radiation induces this disease still remains unknown. Several studies demonstrated that absorption of UV by molecules in the cell results in the generation of ROS, which can cause oxidative DNA damage, often in the form of 8-oxo- or 8-hydroxy-deoxyguanosine (8-OHdG) adducts [<xref ref-type="bibr" rid="r33">33</xref>,<xref ref-type="bibr" rid="r34">34</xref>]. In keratinocytes, this DNA damage leads to an increase in p53 expression [<xref ref-type="bibr" rid="r35">35</xref>], which arrests the cell cycle at G<sub>1</sub>/S and drive the cell through apoptosis if the damage cannot be repaired. This mechanism prevents the accumulation of potentially oncogenic DNA mutations. Therefore, chronic or multiple UV-B exposure can lead to p53 mutation and/or allelic loss [<xref ref-type="bibr" rid="r36">36</xref>,<xref ref-type="bibr" rid="r37">37</xref>] or a UV-induced defect in p53 activation [<xref ref-type="bibr" rid="r20">20</xref>]. Previously, we have observed p53 overexpression in 8-OHdG immunoreactive pterygia, providing evidence that pterygium is a tumor-like growth disorder related to faulty apoptosis [<xref ref-type="bibr" rid="r21">21</xref>].</p><p>Extensive data has validated the role of UV-B as both a tumor initiator and promoter probably by its ability to upregulate COX-2 expression, which converts arachidonic acid into PGH2 [<xref ref-type="bibr" rid="r25">25</xref>]. These products may act as tumor promoters in UV-initiated tissue or they may enhance initiation due to their ability to act as oxidants [<xref ref-type="bibr" rid="r38">38</xref>]. Subbaramaiah et al. [<xref ref-type="bibr" rid="r27">27</xref>] reported that normal p53 suppresses COX-2 expression, suggesting that loss of p53 function may result in the induction of COX-2 expression. COX-2 stimulates tumor cell proliferation and increases the invasiveness of malignant cells [<xref ref-type="bibr" rid="r39">39</xref>] and enhances angiogenesis through the production of vascular endothelial growth factor (VEGF). Finally, a stable overexpression of COX-2 determines a dramatic resistance to UV-induced apoptosis [<xref ref-type="bibr" rid="r40">40</xref>].</p><p>Herein, we have used immunohistochemistry to demonstrate COX-2 expression in 67.7% of pterygial specimens in the cytoplasm of keratinocytes localized in the lower and middle layers of the epithelium whereas no immunoreactivity was detectable in normal conjunctiva. Our data are in agreement with Chiang et al. [<xref ref-type="bibr" rid="r12">12</xref>], who have demonstrated COX-2 expression in primary pterygium. The results support the causal relationship between COX-2 and pterygium and provide molecular evidence of the effects of UV radiation in this lesion.</p><p>Since 1979 [<xref ref-type="bibr" rid="r41">41</xref>], it has been proposed that pterygium could represent a precancerous condition of the mucosal epithelium, analogous to cutaneous actinic keratosis for histologic features [<xref ref-type="bibr" rid="r42">42</xref>]. Actinic keratoses are dysplastic lesions considered to be precursor to squamous cell carcinomas, which result from chronic exposure to sunlight. Buckman and co-authors [<xref ref-type="bibr" rid="r38">38</xref>] demonstrated the prevalence of COX-2 not only in UV-induced human squamous cell carcinoma but also in actinic keratoses.</p><p>Aziz et al. [<xref ref-type="bibr" rid="r29">29</xref>] have demonstrated that UV-B exposure leads to a significant activation of survivin, a protein belonging to the inhibitor of apoptosis (IAP) gene family, in human epidermal keratinocytes. Survivin is expressed in embryonic or proliferating normal adult tissues and highly upregulated in almost all types of human malignancy [<xref ref-type="bibr" rid="r43">43</xref>]. Survivin overexpression inhibits extrinsic or intrinsic apoptotic pathways through an inhibition of caspases [<xref ref-type="bibr" rid="r44">44</xref>]. Previously, we have demonstrated for the first time an upregulation of survivin expression and a relationship between survivin, oxidative stress, and p53 overexpression in primary pterygia [<xref ref-type="bibr" rid="r5">5</xref>]. We then hypothesized that the cooperation between survivin and UV-induced functional loss of p53 could be responsible for aberrant inhibition of apoptosis in pterygium. In the present study, we have demonstrated a strong significant COX-2 expression in survivin immunoreactive epithelial cells. This is the first study to report a significant correlation between COX-2 upregulation and survivin expression in primary pterygium. Several authors already reported a relationship between COX-2 and survivin expression in other kinds of malignant lesions such as ovarian [<xref ref-type="bibr" rid="r32">32</xref>], breast [<xref ref-type="bibr" rid="r31">31</xref>], and non-small cell lung cancer [<xref ref-type="bibr" rid="r30">30</xref>]. Our results are in agreement with previous data by Erkanly et al. [<xref ref-type="bibr" rid="r45">45</xref>] about the positive correlation of the two proteins not only in the endometrial carcinoma but also in a premalignant lesion such as endometrial hyperplasia. Overall, these data indicate that COX-2 may be involved in pterygium growth by increasing the activation of the anti-apoptotic protein, survivin. Moreover, the relationship between COX-2 and survivin suggest a potential origin of pterygium through an anti-apoptotic mechanism and confirm that this lesion may develop toward a neoplastic-like growth disorder instead of a degenerative condition of the conjunctiva. These evidences provide useful information toward the development of novel therapeutic strategies for pterygium involving the use of COX-2 and survivin inhibitors alone or in combination, which might contribute to the treatment of pterygium through the suppression of the anti-apoptotic effect of survivin and the tumorigenic induction of COX-2.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was supported by grants from the Ministero degli Affari Esteri (MAE) and Fondazione Banco di Sardegna (Italy). Particular thanks are due to Dr. Maria Isabel Sanchez, Mrs. Maria Itala Mosso, and Mr. Massimo Annis for their skillful technical assistance. The authors are grateful to the Sociedad de Oftalmologia de Cuenca (Ecuador) for their help in enrollment and follow-up.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Girolamo</surname><given-names>N</given-names></name><name><surname>McCluskey</surname><given-names>P</given-names></name><name><surname>Lloyd</surname><given-names>A</given-names></name><name><surname>Coroneo</surname><given-names>MT</given-names></name><name><surname>Wakefield</surname><given-names>D</given-names></name></person-group><article-title>Expression of MMPs and TIMPs in human pterygia and cultured pterygium epithelial cells.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2000</year><volume>41</volume><fpage>671</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10711680</pub-id></citation></ref><ref id="r2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pinkerton</surname><given-names>OD</given-names></name><name><surname>Hokama</surname><given-names>Y</given-names></name><name><surname>Shigemura</surname><given-names>LA</given-names></name></person-group><article-title>Immunologic basis for the pathogenesis of pterygium.</article-title><source>Am J Ophthalmol</source><year>1984</year><volume>98</volume><fpage>225</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">6383051</pub-id></citation></ref><ref id="r3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perra</surname><given-names>MT</given-names></name><name><surname>Maxia</surname><given-names>C</given-names></name><name><surname>Zucca</surname><given-names>I</given-names></name><name><surname>Piras</surname><given-names>F</given-names></name><name><surname>Sirigu</surname><given-names>P</given-names></name></person-group><article-title>Immunohistochemical study of human pterygium.</article-title><source>Histol Histopathol</source><year>2002</year><volume>17</volume><fpage>139</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">11813864</pub-id></citation></ref><ref id="r4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>DT</given-names></name><name><surname>Tang</surname><given-names>WY</given-names></name><name><surname>Liu</surname><given-names>YP</given-names></name><name><surname>Goh</surname><given-names>HS</given-names></name><name><surname>Smith</surname><given-names>DR</given-names></name></person-group><article-title>Apoptosis and apoptosis related gene expression in normal conjunctiva and pterygium.</article-title><source>Br J Ophthalmol</source><year>2000</year><volume>84</volume><fpage>212</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10655200</pub-id></citation></ref><ref id="r5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maxia</surname><given-names>C</given-names></name><name><surname>Perra</surname><given-names>MT</given-names></name><name><surname>Demurtas</surname><given-names>P</given-names></name><name><surname>Minerba</surname><given-names>L</given-names></name><name><surname>Murtas</surname><given-names>D</given-names></name><name><surname>Piras</surname><given-names>F</given-names></name><name><surname>Corbu</surname><given-names>A</given-names></name><name><surname>Gotuzzo</surname><given-names>DC</given-names></name><name><surname>Cabrera</surname><given-names>GR</given-names></name><name><surname>Ribatti</surname><given-names>D</given-names></name><name><surname>Sirigu</surname><given-names>P</given-names></name></person-group><article-title>Expression of survivin protein in pterygium and relationship with oxidative DNA damage.</article-title><source>J Cell Mol Med</source><year>2008</year><volume>12</volume><issue>6a</issue><fpage>2372</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">18266976</pub-id></citation></ref><ref id="r6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Girolamo</surname><given-names>N</given-names></name><name><surname>Kumar</surname><given-names>RK</given-names></name><name><surname>Coroneo</surname><given-names>MT</given-names></name><name><surname>Wakefield</surname><given-names>D</given-names></name></person-group><article-title>UVB-mediated induction of interleukin-6 and &#x02212;8 in pterygia and cultured human pterygium epithelial cells.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2002</year><volume>43</volume><fpage>3430</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12407153</pub-id></citation></ref><ref id="r7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kria</surname><given-names>L</given-names></name><name><surname>Ohira</surname><given-names>A</given-names></name><name><surname>Amemiya</surname><given-names>T</given-names></name></person-group><article-title>Growth factors in cultured pterygium fibroblasts: immunohistochemical and ELISA analysis.</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>1998</year><volume>236</volume><fpage>702</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9782432</pub-id></citation></ref><ref id="r8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ribatti</surname><given-names>D</given-names></name><name><surname>Nico</surname><given-names>B</given-names></name><name><surname>Maxia</surname><given-names>C</given-names></name><name><surname>Longo</surname><given-names>V</given-names></name><name><surname>Murtas</surname><given-names>D</given-names></name><name><surname>Mangieri</surname><given-names>D</given-names></name><name><surname>Perra</surname><given-names>MT</given-names></name><name><surname>De Giorgis</surname><given-names>M</given-names></name><name><surname>Piras</surname><given-names>F</given-names></name><name><surname>Crivellato</surname><given-names>E</given-names></name><name><surname>Sirigu</surname><given-names>P</given-names></name></person-group><article-title>Neovascularization and mast cells with tryptase activity increase simultaneously in human pterygium.</article-title><source>J Cell Mol Med</source><year>2007</year><volume>11</volume><fpage>585</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17635650</pub-id></citation></ref><ref id="r9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Detorakis</surname><given-names>ET</given-names></name><name><surname>Drakonaki</surname><given-names>EE</given-names></name><name><surname>Spandidos</surname><given-names>DA</given-names></name></person-group><article-title>Molecular genetic alterations and viral presence in ophthalmic pterygium.</article-title><source>Int J Mol Med</source><year>2000</year><volume>6</volume><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">10851263</pub-id></citation></ref><ref id="r10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piras</surname><given-names>F</given-names></name><name><surname>Moore</surname><given-names>PS</given-names></name><name><surname>Ugalde</surname><given-names>J</given-names></name><name><surname>Perra</surname><given-names>MT</given-names></name><name><surname>Scarpa</surname><given-names>A</given-names></name><name><surname>Sirigu</surname><given-names>P</given-names></name></person-group><article-title>Detection of human papillomavirus DNA in pterygia from different geographical regions.</article-title><source>Br J Ophthalmol</source><year>2003</year><volume>87</volume><fpage>864</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12812887</pub-id></citation></ref><ref id="r11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chui</surname><given-names>J</given-names></name><name><surname>Di Girolamo</surname><given-names>N</given-names></name><name><surname>Wakefield</surname><given-names>D</given-names></name><name><surname>Coroneo</surname><given-names>MT</given-names></name></person-group><article-title>The pathogenesis of pterygium: current concepts and their therapeutic implications.</article-title><source>Ocul Surf</source><year>2008</year><volume>6</volume><fpage>24</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">18264653</pub-id></citation></ref><ref id="r12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>CC</given-names></name><name><surname>Cheng</surname><given-names>YW</given-names></name><name><surname>Lin</surname><given-names>CL</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Tsai</surname><given-names>FJ</given-names></name><name><surname>Tseng</surname><given-names>SH</given-names></name><name><surname>Tsai</surname><given-names>YY</given-names></name></person-group><article-title>Cyclooxygenase 2 expression in pterygium.</article-title><source>Mol Vis</source><year>2007</year><volume>13</volume><fpage>635</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17515883</pub-id></citation></ref><ref id="r13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Girolamo</surname><given-names>N</given-names></name><name><surname>Wakefield</surname><given-names>D</given-names></name><name><surname>Coroneo</surname><given-names>MT</given-names></name></person-group><article-title>UVB-mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signaling.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2006</year><volume>47</volume><fpage>2430</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16723453</pub-id></citation></ref><ref id="r14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Detorakis</surname><given-names>ET</given-names></name><name><surname>Zafiropoulos</surname><given-names>A</given-names></name><name><surname>Arvanitis</surname><given-names>DA</given-names></name><name><surname>Spandidos</surname><given-names>DA</given-names></name></person-group><article-title>Detection of point mutations at codon 12 of KI-ras in ophthalmic pterygia.</article-title><source>Eye</source><year>2005</year><volume>19</volume><fpage>210</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15232598</pub-id></citation></ref><ref id="r15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>YY</given-names></name><name><surname>Cheng</surname><given-names>YW</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Tsai</surname><given-names>FJ</given-names></name><name><surname>Tseng</surname><given-names>SH</given-names></name><name><surname>Lin</surname><given-names>CL</given-names></name><name><surname>Chang</surname><given-names>KC</given-names></name></person-group><article-title>Oxidative DNA damage in pterygium.</article-title><source>Mol Vis</source><year>2005</year><volume>11</volume><fpage>71</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15692461</pub-id></citation></ref><ref id="r16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reisman</surname><given-names>D</given-names></name><name><surname>McFadden</surname><given-names>JW</given-names></name><name><surname>Lu</surname><given-names>G</given-names></name></person-group><article-title>Loss of heterozygosity and p53 expression in pterygium.</article-title><source>Cancer Lett</source><year>2004</year><volume>206</volume><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">15019163</pub-id></citation></ref><ref id="r17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dushku</surname><given-names>N</given-names></name><name><surname>Reid</surname><given-names>TW</given-names></name></person-group><article-title>P53 expression in altered limbal basal cells of pingueculae, pterygia, and limbal tumors.</article-title><source>Curr Eye Res</source><year>1997</year><volume>16</volume><fpage>1179</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">9426949</pub-id></citation></ref><ref id="r18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>DT</given-names></name><name><surname>Lim</surname><given-names>AS</given-names></name><name><surname>Goh</surname><given-names>HS</given-names></name><name><surname>Smith</surname><given-names>DR</given-names></name></person-group><article-title>Abnormal expression of the p53 tumor suppressor gene in the conjunctiva of patients with pterygium.</article-title><source>Am J Ophthalmol</source><year>1997</year><volume>123</volume><fpage>404</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">9063255</pub-id></citation></ref><ref id="r19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>YY</given-names></name><name><surname>Cheng</surname><given-names>YW</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Tsai</surname><given-names>FJ</given-names></name><name><surname>Tseng</surname><given-names>SH</given-names></name><name><surname>Chang</surname><given-names>KC</given-names></name></person-group><article-title>P53 gene mutation spectrum and the relationship between gene mutation and protein levels in pterygium.</article-title><source>Mol Vis</source><year>2005</year><volume>11</volume><fpage>50</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15682042</pub-id></citation></ref><ref id="r20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>BG</given-names></name><name><surname>John-Aryankalayil</surname><given-names>M</given-names></name><name><surname>Rowsey</surname><given-names>JJ</given-names></name><name><surname>Dushku</surname><given-names>N</given-names></name><name><surname>Reid</surname><given-names>TW</given-names></name></person-group><article-title>Accumulation of p53 protein in pterygia is not accompanied by TP53 gene mutation.</article-title><source>Exp Eye Res</source><year>2006</year><volume>82</volume><fpage>91</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16005868</pub-id></citation></ref><ref id="r21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perra</surname><given-names>MT</given-names></name><name><surname>Maxia</surname><given-names>C</given-names></name><name><surname>Corbu</surname><given-names>A</given-names></name><name><surname>Minerba</surname><given-names>L</given-names></name><name><surname>Demurtas</surname><given-names>P</given-names></name><name><surname>Colombari</surname><given-names>R</given-names></name><name><surname>Murtas</surname><given-names>D</given-names></name><name><surname>Bravo</surname><given-names>S</given-names></name><name><surname>Piras</surname><given-names>F</given-names></name><name><surname>Sirigu</surname><given-names>P</given-names></name></person-group><article-title>Oxidative stress in pterygium: relationship between p53 and 8-hydroxydeoxyguanosine.</article-title><source>Mol Vis</source><year>2006</year><volume>12</volume><fpage>1136</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">17093398</pub-id></citation></ref><ref id="r22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perra</surname><given-names>MT</given-names></name><name><surname>Colombari</surname><given-names>R</given-names></name><name><surname>Maxia</surname><given-names>C</given-names></name><name><surname>Zucca</surname><given-names>I</given-names></name><name><surname>Piras</surname><given-names>F</given-names></name><name><surname>Corbu</surname><given-names>A</given-names></name><name><surname>Bravo</surname><given-names>S</given-names></name><name><surname>Scarpa</surname><given-names>A</given-names></name><name><surname>Sirigu</surname><given-names>P</given-names></name></person-group><article-title>Finding of conjunctival melanocytic pigmented lesions within pterygium.</article-title><source>Histopathology</source><year>2006</year><volume>48</volume><fpage>387</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">16487360</pub-id></citation></ref><ref id="r23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bickers</surname><given-names>DR</given-names></name><name><surname>Athar</surname><given-names>M</given-names></name></person-group><article-title>Oxidative stress in the pathogenesis of skin disease.</article-title><source>J Invest Dermatol</source><year>2006</year><volume>126</volume><fpage>2565</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">17108903</pub-id></citation></ref><ref id="r24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sarkar</surname><given-names>FH</given-names></name><name><surname>Adsule</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Padhye</surname><given-names>S</given-names></name></person-group><article-title>Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy.</article-title><source>Mini Rev Med Chem</source><year>2007</year><volume>7</volume><fpage>599</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">17584158</pub-id></citation></ref><ref id="r25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herschman</surname><given-names>HR</given-names></name></person-group><article-title>Prostaglandin synthase 2.</article-title><source>Biochim Biophys Acta</source><year>1996</year><volume>1299</volume><fpage>125</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">8555245</pub-id></citation></ref><ref id="r26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rundhaug</surname><given-names>JE</given-names></name><name><surname>Fischer</surname><given-names>SM</given-names></name></person-group><article-title>Cyclo-oxygenase-2 plays a critical role in UV-induced skin carcinogenesis.</article-title><source>Photochem Photobiol</source><year>2008</year><volume>84</volume><fpage>322</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18194346</pub-id></citation></ref><ref id="r27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Subbaramaiah</surname><given-names>K</given-names></name><name><surname>Altorki</surname><given-names>N</given-names></name><name><surname>Chung</surname><given-names>WJ</given-names></name><name><surname>Mestre</surname><given-names>JR</given-names></name><name><surname>Sampat</surname><given-names>A</given-names></name><name><surname>Dannenberg</surname><given-names>AJ</given-names></name></person-group><article-title>Inhibition of cyclooxygenase-2 gene expression by p53.</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>10911</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">10196169</pub-id></citation></ref><ref id="r28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koki</surname><given-names>AT</given-names></name><name><surname>Khan</surname><given-names>NK</given-names></name><name><surname>Woerner</surname><given-names>BM</given-names></name><name><surname>Seibert</surname><given-names>K</given-names></name><name><surname>Harmon</surname><given-names>JL</given-names></name><name><surname>Dannenberg</surname><given-names>AJ</given-names></name><name><surname>Soslow</surname><given-names>RA</given-names></name><name><surname>Masferrer</surname><given-names>JL</given-names></name></person-group><article-title>Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers.</article-title><source>Prostaglandins Leukot Essent Fatty Acids</source><year>2002</year><volume>66</volume><fpage>13</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12051953</pub-id></citation></ref><ref id="r29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aziz</surname><given-names>MH</given-names></name><name><surname>Ghotra</surname><given-names>AS</given-names></name><name><surname>Shukla</surname><given-names>Y</given-names></name><name><surname>Ahmad</surname><given-names>N</given-names></name></person-group><article-title>Ultraviolet-B radiation causes an upregulation of survivin in human keratinocytes and mouse skin.</article-title><source>Photochem Photobiol</source><year>2004</year><volume>80</volume><fpage>602</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15623349</pub-id></citation></ref><ref id="r30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krysan</surname><given-names>K</given-names></name><name><surname>Merchant</surname><given-names>FH</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Dohadwala</surname><given-names>M</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name></person-group><article-title>Heuze-Vourc'h N, P&#x000f5;ld M, Seligson D, Chia D, Goodglick L, Wang H, Strieter R, Sharma S, Dubinett S. COX-2-dependent stabilization of survivin in non-small cell lung cancer.</article-title><source>FASEB J</source><year>2004</year><volume>18</volume><fpage>206</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">14597555</pub-id></citation></ref><ref id="r31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>N</given-names></name><name><surname>Haywood</surname><given-names>P</given-names></name><name><surname>Flint</surname><given-names>P</given-names></name><name><surname>Knox</surname><given-names>WF</given-names></name><name><surname>Bundred</surname><given-names>NJ</given-names></name></person-group><article-title>Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.</article-title><source>Br J Cancer</source><year>2006</year><volume>94</volume><fpage>253</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16421596</pub-id></citation></ref><ref id="r32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Athanassiadou</surname><given-names>P</given-names></name><name><surname>Grapsa</surname><given-names>D</given-names></name><name><surname>Athanassiades</surname><given-names>P</given-names></name><name><surname>Gonidi</surname><given-names>M</given-names></name><name><surname>Athanassiadou</surname><given-names>AM</given-names></name><name><surname>Tsipis</surname><given-names>A</given-names></name><name><surname>Patsouris</surname><given-names>E</given-names></name></person-group><article-title>The prognostic significance of COX-2 and survivin expression in ovarian cancer.</article-title><source>Pathol Res Pract</source><year>2008</year><volume>204</volume><fpage>241</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18171606</pub-id></citation></ref><ref id="r33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hattori</surname><given-names>Y</given-names></name><name><surname>Nishigori</surname><given-names>C</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Uchida</surname><given-names>K</given-names></name><name><surname>Nikaido</surname><given-names>O</given-names></name><name><surname>Osawa</surname><given-names>T</given-names></name><name><surname>Hiai</surname><given-names>H</given-names></name><name><surname>Imamura</surname><given-names>S</given-names></name><name><surname>Toyokuni</surname><given-names>S</given-names></name></person-group><article-title>8-hydroxy-2'-deoxyguanosine is increased in epidermal cells of hairless mice after chronic ultraviolet B exposure.</article-title><source>J Invest Dermatol</source><year>1996</year><volume>107</volume><fpage>733</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8875958</pub-id></citation></ref><ref id="r34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilgus</surname><given-names>TA</given-names></name><name><surname>Koki</surname><given-names>AT</given-names></name><name><surname>Zweifel</surname><given-names>BS</given-names></name><name><surname>Kusewitt</surname><given-names>DF</given-names></name><name><surname>Rubal</surname><given-names>PA</given-names></name><name><surname>Oberyszyn</surname><given-names>TM</given-names></name></person-group><article-title>Inhibition of cutaneous ultraviolet B-mediated inflammation and tumor formation with topical celecoxib treatment.</article-title><source>Mol Carcinog</source><year>2003</year><volume>38</volume><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">14502644</pub-id></citation></ref><ref id="r35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>YP</given-names></name><name><surname>Lou</surname><given-names>YR</given-names></name><name><surname>Yen</surname><given-names>P</given-names></name><name><surname>Mitchell</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>MT</given-names></name><name><surname>Conney</surname><given-names>AH</given-names></name></person-group><article-title>Time course for early adaptive responses to ultraviolet B light in the epidermis of SKH-1 mice.</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>4591</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">10493513</pub-id></citation></ref><ref id="r36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kraemer</surname><given-names>KH</given-names></name></person-group><article-title>Sunlight and skin cancer: another link revealed.</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>11</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">8990152</pub-id></citation></ref><ref id="r37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ouhtit</surname><given-names>A</given-names></name><name><surname>Muller</surname><given-names>HK</given-names></name><name><surname>Gorny</surname><given-names>A</given-names></name><name><surname>Ananthaswamy</surname><given-names>HN</given-names></name></person-group><article-title>UVB-induced experimental carcinogenesis: dysregulation of apoptosis and p53 signalling pathway.</article-title><source>Redox Rep</source><year>2000</year><volume>5</volume><fpage>128</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10939292</pub-id></citation></ref><ref id="r38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buckman</surname><given-names>SY</given-names></name><name><surname>Gresham</surname><given-names>A</given-names></name><name><surname>Hale</surname><given-names>P</given-names></name><name><surname>Hruza</surname><given-names>G</given-names></name><name><surname>Anast</surname><given-names>J</given-names></name><name><surname>Masferrer</surname><given-names>J</given-names></name><name><surname>Pentland</surname><given-names>AP</given-names></name></person-group><article-title>COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer.</article-title><source>Carcinogenesis</source><year>1998</year><volume>19</volume><fpage>723</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9635856</pub-id></citation></ref><ref id="r39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Joo</surname><given-names>YE</given-names></name><name><surname>Chung</surname><given-names>IJ</given-names></name><name><surname>Park</surname><given-names>YK</given-names></name><name><surname>Koh</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>CH</given-names></name><name><surname>Lee</surname><given-names>WS</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Choi</surname><given-names>SK</given-names></name><name><surname>Rew</surname><given-names>JS</given-names></name><name><surname>Park</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name></person-group><article-title>Expression of cyclooxygenase-2, p53 and Ki-67 in gastric cancer.</article-title><source>J Korean Med Sci</source><year>2006</year><volume>21</volume><fpage>871</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17043422</pub-id></citation></ref><ref id="r40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tjiu</surname><given-names>JW</given-names></name><name><surname>Liao</surname><given-names>YH</given-names></name><name><surname>Lin</surname><given-names>SJ</given-names></name><name><surname>Huang</surname><given-names>YL</given-names></name><name><surname>Tsai</surname><given-names>WL</given-names></name><name><surname>Chu</surname><given-names>CY</given-names></name><name><surname>Kuo</surname><given-names>ML</given-names></name><name><surname>Jee</surname><given-names>SH</given-names></name></person-group><article-title>Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis.</article-title><source>J Invest Dermatol</source><year>2006</year><volume>126</volume><fpage>1143</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">16528365</pub-id></citation></ref><ref id="r41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clear</surname><given-names>AS</given-names></name><name><surname>Chirambo</surname><given-names>MC</given-names></name><name><surname>Hutt</surname><given-names>MS</given-names></name></person-group><article-title>Solar keratosis, pterygium, and squamous cell carcinoma of the conjunctiva in Malawi.</article-title><source>Br J Ophthalmol</source><year>1979</year><volume>63</volume><fpage>102</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">427069</pub-id></citation></ref><ref id="r42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>TK</given-names></name><name><surname>Jin</surname><given-names>KH</given-names></name></person-group><article-title>Telomerase activity in pterygeal and normal conjunctival epithelium.</article-title><source>Korean J Ophthalmol</source><year>2000</year><volume>14</volume><fpage>85</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11213740</pub-id></citation></ref><ref id="r43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group><article-title>Survivin, cancer networks and pathway-directed drug discovery.</article-title><source>Nat Rev Cancer</source><year>2008</year><volume>8</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">18075512</pub-id></citation></ref><ref id="r44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zaffaroni</surname><given-names>N</given-names></name><name><surname>Pennati</surname><given-names>M</given-names></name><name><surname>Colella</surname><given-names>G</given-names></name><name><surname>Perego</surname><given-names>P</given-names></name><name><surname>Supino</surname><given-names>R</given-names></name><name><surname>Gatti</surname><given-names>L</given-names></name><name><surname>Pilotti</surname><given-names>S</given-names></name><name><surname>Zunino</surname><given-names>F</given-names></name><name><surname>Daidone</surname><given-names>MG</given-names></name></person-group><article-title>Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer.</article-title><source>Cell Mol Life Sci</source><year>2002</year><volume>59</volume><fpage>1406</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">12363043</pub-id></citation></ref><ref id="r45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Erkanli</surname><given-names>S</given-names></name><name><surname>Bolat</surname><given-names>F</given-names></name><name><surname>Kayaselcuk</surname><given-names>F</given-names></name><name><surname>Demirhan</surname><given-names>B</given-names></name><name><surname>Kuscu</surname><given-names>E</given-names></name></person-group><article-title>COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma.</article-title><source>Gynecol Oncol</source><year>2007</year><volume>104</volume><fpage>320</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">17030351</pub-id></citation></ref></ref-list></back></article> 